Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization.
| Product Name | Tasisulam |
| Synonyms | |
| CAS Number | 519055-62-0 |
| Related CAS | |
| Molecular Formula | C11H6BrCl2NO3S2 |
| Molecular Weight | 415.1 |
| SMILES | ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1 |
| Purity (HPLC) | >= 95% |
| Physical Appearance | White solid |
| Solubility | DMSO, DMF |
| Shipping Conditions | Room Temperature |
| Storage Conditions | Refrigerated |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D.,Qin, J.-J., Protein degradation technology: a strategic paradigm shift in drug discovery. Journal of Hematology & Oncology 2021, 14, 138.Xu, Y., Nijhuis, A.,Keun, H. C., RNA-binding motif protein 39 (RBM39): An emerging cancer target. British Journal of Pharmacology n/a.
Documents
Datasheet COA MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.